“Brilliant strategist on complex technical and legal issues.”
“She has excellent instincts, is sharp and intuitive and has an innate ability to understand a pharmaceutical client's business.”
Biography
Elizabeth Holland is a first-chair trial lawyer who focuses exclusively on representing innovators in patent infringement and related litigation in the life sciences space.
With more than 35 years of experience, Elizabeth has served as lead counsel for pharmaceutical, biotech and medical device companies in numerous patent infringement litigations, licensing disputes, trade secret litigations, arbitrations, IPR proceedings and Federal Circuit appeals. She has expertise in Hatch-Waxman and BPCIA litigation, as well as disputes between innovator companies. Elizabeth is consistently ranked among the top lawyers in her field by publications such as Chambers Global, Chambers USA, IAM Patent 1000, The Legal 500 US, Managing Intellectual Property, LMG Life Sciences and Euromoney, which have noted her "assured handling of even the most complex pharmaceuticals patent cases" and have described her as "exactly what you want in a first-chair lawyer; she is very skilled in the courtroom, very adept at managing multiple important cases, and well-liked by judges."
Elizabeth has also been noted as being "exceptional on her feet in court;" getting "excellent results;" and "understanding clients' business goals and litigating with those in mind." She is a three-time winner of LMG Life Sciences "Hatch Waxman Litigator of the Year" and has been featured as a "Winning Litigator" by The National Law Journal.
Over the course of her career, Elizabeth has served on law firm Executive, Management, and Partnership committees and has chaired Inclusion Committees.
Experience
Wins in S.D.N.Y. and U.S. Supreme Court in patent litigation on the drug Copaxone®, including landmark decision on claim construction.*
Wins in D.N.J. (after trial) and Federal Circuit in patent litigation on the drug Atelvia®.*
Win in D. Del. (after trial) in patent litigation concerning the drug Quillivant®.*
Multiple wins in D. Del. and Federal Circuit in patent litigation on the drug Uceris®, including judgment under Rule 52(c) and award of attorney’s fees.*
Wins at PTAB on IPRs on patents on the drug Ravicti®.*
Win in D. Mass. (after trial) in patent litigation on the drug Relafen®. Achieved favorable settlement while on appeal.*
Wins in D. Del. (on summary judgment) and Federal Circuit in patent litigation concerning coronary stents.*
Wins in S.D.N.Y. (on summary judgment) and Federal Circuit in competitor patent litigation on pertussis vaccines.*
Win in D.N.J. in a false advertising case concerning x-ray contrast agents.*
Numerous favorable settlements on behalf of clients.*
*Experience prior to joining White & Case.
magna cum laude
The Cooper Union
Band 2: Life Sciences: IP/Patent Litigation - Nationwide, Chambers USA, 2018 - 2025
Band 2: Intellectual Property: Patent - New York, Chambers USA, 2013 – 2025
Band 3: Intellectual Property - Nationwide, Chambers USA, 2021 - 2025
Top 250 Women in IP, Managing Intellectual Property, 2013-2025
Patent Star, Managing Intellectual Property IP Stars, 2013-2025
IAM Patent 1000 - United States: New York – Gold – Individuals: litigation, 2021 - 2025
Best Lawyers in America - Biotechnology and Life Sciences Practice and Litigation: Intellectual Property, 2025
3x Winner, LMG Life Sciences Awards Hatch-Waxman Litigator of the Year
Top 250 Women in Litigation, Benchmark Litigation
Top 10% of practitioners (of more than 5,000 lawyers), Patexia IPR Intelligence Report
Top 50 Women in PTAB Trials, PTAB Bar Association
Leading practitioner for Life Sciences in U.S., Women in Business Law, Expert Guides
Named a Winning Litigator, National Law Journal
Past recipient, Euromoney Women in Business Law Best in Life Sciences Award
Law 360 Intellectual Property section editorial board